Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04105270
Title P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Masonic Cancer Center, University of Minnesota
Indications

lung adenocarcinoma

Therapies

Carboplatin + Durvalumab + Pemetrexed Disodium

Cisplatin + Durvalumab + Pemetrexed Disodium

Durvalumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Masonic Cancer Center, University of Minnesota Minneapolis Minnesota 55455 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field